The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 82.50
Bid: 80.00
Ask: 85.00
Change: 0.00 (0.00%)
Spread: 5.00 (6.25%)
Open: 82.50
High: 82.50
Low: 82.50
Prev. Close: 82.50
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

12 month contract for Sussex CDC pilot extension

6 Sep 2022 07:00

RNS Number : 3346Y
Feedback PLC
06 September 2022
 

 

Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement, this information is now considered to be in the public domain.

 

 

Feedback plc

 

 

Feedback awarded twelve month contract for pilot extension in Sussex Community Diagnostic Centre

 

· £450,000 contract to cover a 12 month extension of initial pilot phase of Sussex Health and Care Partnership Integrated Care System ("Sussex ICS") development programme with Queen Victoria Hospital ("QVH").

· Follows on from the previously announced memorandum of understanding ("MOU") to embark on a pilot scheme, providing services with the exemplar Sussex ICS Community Diagnostic Centre ("CDC") site at QVH.

· The contract enables extension of the current pilot programme whilst QVH embarks on a formal procurement process for a solution in the long term. This procurement is anticipated to be completed in March 2023. The Company will submit a bid in this subsequent procurement.

 

London, 6th September 2022: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical infrastructure company, announces that it has been awarded a twelve-month contract to provide its CDC solution in order to facilitate an extension of the current CDC pilot in Sussex to further GP practices and to enable the adoption of further clinical pathways. The discounted contract is valued at £450,000 and covers the period from 31st March 2022 when the pilot MOU formally ended. The contract will run until 31st March 2023 by which point QVH expect to have concluded a formal procurement for the next phase of the CDC programme rollout, as is required by NHS procurement policies. Feedback intends to submit a bid in this subsequent procurement phase.

 

The contract comes as the first live patients go through the CDC pilot as a result of the MOU signed with the Sussex ICS in October 2021, which was to embark on a pilot scheme to establish symptom-based pathway models for CDC services using Feedback's digital infrastructure solutions Bleepa and CareLocker. QVH in Sussex is one of the UK's exemplar CDC sites and the first to deliver end-to-end symptom-based pathways through the CDC programme. As previously announced, the deployment of Feedback's product suite in the Sussex ICS is intended to be used as a blueprint model for future CDC digital infrastructure models across the UK.

 

Bleepa's patient-centric design enables clinicians to collaborate on a patient-by-patient basis across geography, with the clinical discussion forming an auditable record for the patient episode that is subsequently shared with all stakeholders. CareLocker's ability to integrate with multiple clinical systems and centralise data around an individual patient means that all the diagnostic results can be seen in one place across all provider groups, ensuring that relevant data can be collected from multiple clinical settings, travels with the patient and is always available to clinicians.

 

 

Dr Tom Oakley, CEO of Feedback, said: "QVH and the broader Sussex team have been great partners in delivering this end-to-end clinical solution. This contract recognises the initial stage of our work together and enables us to proceed to a more formal working arrangement, pending a successful procurement exercise.

 

Together we have demonstrated that CDCs can be used to successfully deliver cross-provider symptom-based diagnostic pathways that transform the patient journey within the NHS and we expect to be able to show a meaningful impact on patient waiting lists as a result. ICSs need to adopt a symptom-based pathway approach to CDCs if they are going to deliver the expected impact on cancer and elective care waiting times. This pilot is the first example in the country of how this can be delivered and our digital infrastructure is an essential component of delivering it."

 

Further information on Feedback and its products can be found on the Company's website: https://fbkmed.com/feedback-plc/reports-and-presentations/

 

 

 

-Ends-

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Anesh Patel, CFO

+44 (0) 20 3997 7634

IR@fbk.com

 

Panmure Gordon (UK) Limited (NOMAD and Broker)

Emma Earl/Freddy Crossley (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

 

Walbrook PR Ltd

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Paul McManus/Nick Rome/Joe Walker

07980 541 893 or 07748 325 236 or 07407 020 470

 

 

About Feedback

Feedback plc helps clinical teams to make better decisions faster for patients. We design products that enhance clinician access to patient data and to their colleagues. Our unique approach centres around individual patient episodes, into which we pull relevant clinical data from hospital systems and around which we build remote clinical teams for collaboration. As a result, we produce a digital infrastructure that makes patient data available to clinicians in multiple settings, in a format that enables them to meaningfully interact with it, providing flexibility to clinicians and free movement of patients between provider settings - clinicians can practice from anywhere and patients can attend any care provider for investigation and treatment.

 

Our products Bleepa and CareLocker work together to deliver unparalleled value to our customers. Bleepa is our application layer and sits on top of CareLocker as our data layer. Bleepa is a clinician facing platform that displays clinical results from a patient's CareLocker at a certified and regulated quality, that is suitable for clinical use and enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record. CareLocker provides an alternative to traditional system/cloud storage and stores clinical data at an individual patient level, wrapping relevant clinical data around the specific patient, ensuring that data is always linked to the patient and is available to them and any care setting that they attend - it is a federated data architecture with the patient as the tenant.

 

The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based revenue model is expected to provide increasing levels of visibility as the Company grows its customer base. 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTLAMFTMTTMBLT
Date   Source Headline
2nd Nov 20217:00 amRNSFinal Results
19th Oct 20217:00 amRNSPilot Scheme with Sussex Integrated Care System
11th Oct 20217:00 amRNSMOU with Quest Teleradiology
29th Sep 20217:00 amRNSFeedback Joins NHS AI Procurement Framework
23rd Sep 20217:00 amRNSOfficial Launch of Bleepa Box
14th Sep 20217:00 amRNSMemorandum of Understanding with Qure.ai
9th Sep 20217:00 amRNSLaunch of CareLocker to enhance Bleepa technology
25th Aug 20217:00 amRNSChange of Adviser
3rd Aug 20217:00 amRNSDigital Health article highlights Bleepa potential
16th Jul 20217:00 amRNSBleepa agreement with CVS Equine Division
5th Jul 202110:17 amRNSHolding(s) in Company
30th Jun 20213:30 pmRNSBoard Update
29th Jun 20217:00 amRNSUK Medical Device Certification for Bleepa
10th Jun 20217:00 amRNSBleepa available on Apple App Store & Google Play
8th Jun 20217:00 amRNSYear End Trading Update
6th May 20217:00 amRNSExecutive Appointment
24th Mar 20217:00 amRNSRoyal Berkshire NHS Foundation Trust Contract
23rd Feb 20217:00 amRNSHalf-year Report
19th Jan 20217:00 amRNSBleepa builds on robust data management security
4th Dec 20207:00 amRNSBleepa to join DIT’s first virtual event to India
10th Nov 20209:06 amRNSSelected for Digitalhealth.London 2020 Programme
6th Nov 20203:03 pmRNSResult of Annual General Meeting - Amendment
6th Nov 20201:50 pmRNSHolding(s) in Company
5th Nov 20201:23 pmRNSResult of AGM
5th Nov 20207:01 amRNSBleepa selected for WISH 2020 Innovation Awards
5th Nov 20207:00 amRNSAGM Statement
28th Oct 20203:10 pmRNSDirector/PDMR Shareholding
20th Oct 20207:00 amRNSBleepa adds 3D Imaging with Axial3D Partnership
13th Oct 20207:00 amRNSFinal Results
26th Aug 20201:34 pmRNSHolding(s) in Company
7th Aug 20207:00 amRNSDirector/PDMR Shareholding
5th Aug 20204:36 pmRNSPrice Monitoring Extension
31st Jul 20205:00 pmRNSTotal Voting Rights
30th Jul 20203:48 pmRNSBleepa appointed to major NHSx framework
29th Jul 20202:06 pmRNSSecond Price Monitoring Extn
29th Jul 20202:00 pmRNSPrice Monitoring Extension
15th Jul 20207:00 amRNSAppointment of Non-Executive Director
10th Jul 20207:00 amRNSHolding(s) in Company
7th Jul 20207:00 amRNSHolding(s) in Company
6th Jul 202011:01 amRNSHolding(s) in Company
6th Jul 202010:36 amRNSHolding(s) in Company
6th Jul 20207:00 amRNSHolding(s) in Company
6th Jul 20207:00 amRNSHolding(s) in Company
1st Jul 202012:46 pmRNSResult of Open Offer and General Meeting
25th Jun 202011:59 amRNSDirector/PDMR Shareholding
15th Jun 20207:00 amRNSPlacing, Open Offer and Notice of GM
1st Jun 20207:00 amRNSBleepa® achieves CE Mark
21st May 20207:00 amRNSPapworth NHS Hosp - contract renewal with Bleepa
29th Apr 20202:05 pmRNSSecond Price Monitoring Extn
29th Apr 20202:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.